Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 9;13(Suppl 1):29.
doi: 10.1186/s40248-018-0142-7. eCollection 2018.

When and how ruling out cystic fibrosis in adult patients with bronchiectasis

Affiliations
Review

When and how ruling out cystic fibrosis in adult patients with bronchiectasis

Andrea Gramegna et al. Multidiscip Respir Med. .

Abstract

Background: Bronchiectasis is the final result of different processes and most of the guidelines advocate for a careful evaluation of those etiologies which might be treated or might change patients' management, including cystic fibrosis (CF).

Main body: CFTR mutations have been reported with higher frequency in bronchiectasis population. Although ruling out CF is considered as a main step for etiological screening in bronchiectasis, CF testing lacks of a standardized approach both from a research and clinical point of view. In this review a list of most widely used tests in CF is provided.

Conclusions: Exclusion of CF is imperative for patients with bronchiectasis and CFTR testing should be implemented in usual screening for investigating bronchiectasis etiology. Physicians taking care of bronchiectasis patients should be aware of CFTR testing and its limitations in the adult population. Further studies on CFTR expression in human lung and translational research might elucidate the possible role of CFTR in the pathogenesis of bronchiectasis.

Keywords: Bronchiectasis; CFTR; CFTR gene analysis; Etiological screening; Sweat test.

PubMed Disclaimer

Conflict of interest statement

Not applicable.Not applicable.The authors declare that they have no competing interests. Prof. Francesco Blasi is Editor-in-Chief of Multidisciplinary Respiratory Medicine, whereas Prof. Stefano Aliberti is Associate editor of Multidisciplinary Respiratory Medicine and Guest Editor of the Supplement on Bronchiectasis.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Figure 1
Figure 1
When and how testing patients with bronchiectasis for CF

References

    1. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45:1446–1462. doi: 10.1183/09031936.00119114. - DOI - PubMed
    1. Quint JK, Millet ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–193. doi: 10.1183/13993003.01033-2015. - DOI - PMC - PubMed
    1. Monteagudo M, Rodriguez-Blanco T, Barrechequren M, Simonet P, Miravitlles M. Prevalence and incidence of bronchiectasis in Catalonia, Spain: a population-based study. Respir Med. 2016;121:26–31. doi: 10.1016/j.rmed.2016.10.014. - DOI - PubMed
    1. Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015;46(6):1805–1807. doi: 10.1183/13993003.00954-2015. - DOI - PubMed
    1. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205–209. doi: 10.1097/01.cpm.0000171422.98696.ed. - DOI